Advance Discovery

Through CancerLinQ Discovery®, CancerLinQ provides the oncology research community access to de-identified datasets representing more than 6 million patient records to generate practical knowledge to shape the future of cancer care. Academic, government, non-profit, and industry researchers can use CancerLinQ Discovery datasets to un-lock new insights that can improve patient care and generate new research hypotheses –with the vision of learning from the experience of every cancer patient.

CancerLinQ Discovery Scientific Evidence

Dr. Robert Miller, Medical Director, CancerLinQ

With CancerLinQ Discovery, we are able to expand the information network to anyone in the cancer community.

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

The CancerLinQ staff brings a team approach to getting new researchers up-to-speed, so not utilizing these data sets could be a missed opportunity for your research.

Dr. Robert Miller, Medical Director, CancerLinQ

With CancerLinQ Discovery, we are able to expand the information network to anyone in the cancer community.

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

The CancerLinQ staff brings a team approach to getting new researchers up-to-speed, so not utilizing these data sets could be a missed opportunity for your research.

Dr. Robert Miller, Medical Director, CancerLinQ

With CancerLinQ Discovery, we are able to expand the information network to anyone in the cancer community.

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

The CancerLinQ staff brings a team approach to getting new researchers up-to-speed, so not utilizing these data sets could be a missed opportunity for your research.

CancerLinQ Discovery Data

CancerLinQ Discovery contains data from CancerLinQ’s diverse network of community, academic, and health system care settings, and other data sources such as oncology care pathway tools and registry files. To date, CancerLinQ Discovery data has been used in dozens of publications in addition to efforts focused on advancing clinical development programs.

Discovery Data Brochure

Compare the effectiveness and value of alternative treatment options

Study the use of cancer treatments in populations typically excluded from clinical trials to generate new knowledge to improve patient care.

Deliver insights to inform and revise practice guidelines and quality measures

Subscribing
cancer organizations

100+

Real-world
data representing

6M+ Patients

Different electronic
health record systems

13

Tumor-specific
data sets

10

Available Data Sets

CancerLinQ is proud to offer CancerLinQ Discovery data sets across the following 10 tumor types.

A Community That Learns Together

CancerLinQ Discovery is building a community that learns together and shares insights to improve patient care and outcomes. In 2016, Founding Enterprise Partner AstraZeneca became the first industry strategic partner to join in the mission of CancerLinQ Discovery. Since then, CancerLinQ has established collaborations with government agencies, including the U.S. Food and Drug Administration, medical specialty societies, and other health technology companies. Interested in joining their collaborative community of learning? Email info@cancerlinq.org

Researchers

Advance Discovery

Dr. Robert Miller, Medical Director, CancerLinQ

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

Dr. Robert Miller, Medical Director, CancerLinQ

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

Dr. Robert Miller, Medical Director, CancerLinQ

Thomas Flaig, MD, Vice Chancellor of Research, CU Denver and CU Anschutz Medical Campus

CancerLinQ Discovery Data